Silvia C.
- Country
- Italy
- Department
- Medical Oncology
Research Overview
- Pharmacokinetics Study Comparing GME751 and US/EU-Approved Pembrolizumab in Stage II and III Melanoma Patients Requiring Adjuvant Therapy
- Efficacy Comparison of Nivolumab-Ipilimumab Versus Immune Checkpoint Inhibitor-VEGFR TKI Combinations in Untreated Metastatic Renal Cell Carcinoma
- Phase 3 Multicenter Study Comparing Tivozanib Plus Nivolumab Versus Tivozanib Monotherapy in Renal Cell Carcinoma Post-Immune Checkpoint Inhibitor Therapy
Data & Insights
Has run more than one trial at 94 of 263 partner sites.
Specializations
Renal Cell Carcinoma
The investigator specializes in treating metastatic renal cell carcinoma, with particular expertise in developing therapeutic strategies using immune checkpoint inhibitor combinations and targeted therapies.
- First-line treatment approaches
- VEGFR TKI combination therapies
- Advanced disease management
Their work extends to novel combination approaches for patients who have progressed after initial immunotherapy treatments.
Melanoma Research
The investigator focuses on advancing treatment options for advanced melanoma, particularly in the adjuvant setting for patients with stage III and IV disease.
- Post-surgical treatment strategies
- Immunotherapy applications
- Biosimilar development
Their research encompasses both established treatments and innovative therapeutic alternatives for skin cancer management.
Prostate Cancer
The investigator conducts research in metastatic castration-resistant prostate cancer, exploring novel combination approaches with immunotherapy and targeted agents.
- Novel hormonal therapy optimization
- Combination treatment strategies
- Advanced disease interventions
Their work focuses on developing treatment options for patients with visceral disease and extrapelvic manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.